tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INCY Stock Latest News

Incyte announces CHMP opinion recommending approval of Zynyz combination
The FlyIncyte announces CHMP opinion recommending approval of Zynyz combination
4d ago
INCY
Intel upgraded, Domino’s downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Intel upgraded, Domino’s downgraded: Wall Street’s top analyst calls
14d ago
CE
CVX
Wells downgrades Incyte to Equal Weight on lack of catalysts
PremiumThe Fly
Wells downgrades Incyte to Equal Weight on lack of catalysts
14d ago
INCY
Incyte downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Incyte downgraded to Equal Weight from Overweight at Wells Fargo
14d ago
INCY
Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
PremiumCompany Announcements
Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
18d ago
INCY
Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating
PremiumRatingsIncyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating
20d ago
INCY
Incyte: Post-Jakafi Revenue Gap and Execution Risks Undermine Confidence, Justifying Sell Rating
Premium
Ratings
Incyte: Post-Jakafi Revenue Gap and Execution Risks Undermine Confidence, Justifying Sell Rating
21d ago
INCY
Incyte price target raised to $128 from $101 at TD Cowen
Premium
The Fly
Incyte price target raised to $128 from $101 at TD Cowen
21d ago
INCY
Balancing Near‑Term Strength and Post‑Jakafi Uncertainty: Why Incyte Merits a Hold Rating
PremiumRatings
Balancing Near‑Term Strength and Post‑Jakafi Uncertainty: Why Incyte Merits a Hold Rating
21d ago
INCY
Incyte: Diversifying Beyond Jakafi With a High-Value Late-Stage Pipeline and Disciplined Growth Strategy
PremiumRatings
Incyte: Diversifying Beyond Jakafi With a High-Value Late-Stage Pipeline and Disciplined Growth Strategy
22d ago
INCY
Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors
PremiumCompany Announcements
Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors
25d ago
INCY
Incyte price target raised to $90 from $80 at Goldman Sachs
PremiumThe Fly
Incyte price target raised to $90 from $80 at Goldman Sachs
26d ago
INCY
Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
PremiumCompany AnnouncementsIncyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
27d ago
INCY
3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
Premium
Market News
3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
27d ago
FBT
AAPL
Palvella Therapeutics appoints Vimal Patel as SVP, medical affairs
Premium
The Fly
Palvella Therapeutics appoints Vimal Patel as SVP, medical affairs
27d ago
INCY
PVLA
Balanced Risk-Reward for Incyte as Monjuvi’s Frontline DLBCL Win Offers Modest Upside in a Crowded Market
PremiumRatings
Balanced Risk-Reward for Incyte as Monjuvi’s Frontline DLBCL Win Offers Modest Upside in a Crowded Market
29d ago
INCY
Morning Movers: Incyte gains following frontMIND trial results
PremiumThe Fly
Morning Movers: Incyte gains following frontMIND trial results
29d ago
BKR
CVX
Incyte announces frontMIND trial meets primary, secondary endpoints
PremiumThe Fly
Incyte announces frontMIND trial meets primary, secondary endpoints
29d ago
INCY
Incyte price target raised to $103 from $93 at Truist
PremiumThe Fly
Incyte price target raised to $103 from $93 at Truist
1M ago
INCY
Incyte announces approval of Zynyz combination in Japan
PremiumThe FlyIncyte announces approval of Zynyz combination in Japan
1M ago
INCY
Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
Premium
Company Announcements
Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
2M ago
INCY
Incyte announces European Commission approval of second indication for Minjuvi
Premium
The Fly
Incyte announces European Commission approval of second indication for Minjuvi
2M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >